Neurizon Therapeutics has announced that the first participant in Regimen I of the phase 2/3 HEALEY ALS Platform Trial has completed the 36-week randomised controlled trial phase and moved into the Active Treatment Extension (ATE).
The milestone follows the completion of enrolment in July 2026, when 250 participants were recruited across 78 clinical sites in the US. Under the extension protocol, eligible participants can continue in the study and receive investigational treatment with NUZ-001.
According to the company, the ATE is designed to generate additional long-term safety, tolerability, functional and biomarker data beyond that collected during the placebo-controlled phase. Participants will continue to undergo assessments including ALS Functional Rating Scale-Revised measurements, respiratory function monitoring and quality-of-life evaluations.
Blood and urine biomarker testing, including neurofilament light chain assessments, will also continue throughout the extension period.
Neurizon said the additional observations are expected to complement data gathered during the randomised phase and contribute to the wider clinical evidence package supporting the development of NUZ-001. Treatment assignments will remain blinded during the extension.
The company noted that Regimen I enrolled all 250 participants in around five months, which it described as the fastest enrolment in ALS trial history.
The update also follows recent feedback from the US FDA indicating that positive results from the HEALEY ALS Platform Trial may support a traditional approval pathway, with Regimen I potentially serving as a single registrational study for NUZ-001, subject to regulatory requirements being met.
Dr Chris Bremer, Chief Executive Officer of Neurizon, said: “The first participant entering the Active Treatment Extension is an important milestone for Regimen I and reflects the continued progress of our clinical development program.
“For people living with ALS, a progressive disease with limited treatment options, advancing research into potential new therapies is critically important. We are grateful to the participants who continue to contribute to this research, and to their families and clinical teams for their commitment.”
Merit Cudkowicz, Executive Director of the Mass General Brigham Neuroscience Institute and Director of the Healey & AMG Center for ALS, explained: “We believe strongly that it is critical to design clinical trials to get clear results in the shortest time period.
“After enrolling 250 participants in 5 months, we are excited to now have taken this next step in Regimen I of the HEALEY ALS Platform Trial.”










